Stockscreener 앱 받기
259.70
0.53%
-1.38
시간 외 거래:
259.70
전일 마감가:
$261.08
열려 있는:
$263.36
하루 거래량:
2.77M
Relative Volume:
1.78
시가총액:
$50.53B
수익:
$328.68B
순이익/손실:
$2.55B
주가수익비율:
19.92
EPS:
13.0349
순현금흐름:
$1.56B
1주 성능:
-14.48%
1개월 성능:
-19.05%
6개월 성능:
-28.86%
1년 성능:
-8.23%
1일 변동 폭
$258.15
$264.72
1주일 범위
$244.82
$306.23
52주 변동 폭
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
명칭
Cencora Inc
전화
610-727-7000
주소
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
259.70 | 50.80B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
725.17 | 88.33B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
182.50 | 43.01B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
68.99 | 8.07B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
2.11 | 1.70B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | 재개 | Mizuho | Outperform |
| 2024-09-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-03 | 개시 | Barclays | Overweight |
| 2023-12-14 | 개시 | Wells Fargo | Equal Weight |
| 2023-03-31 | 개시 | Citigroup | Buy |
| 2023-01-31 | 재개 | Evercore ISI | Outperform |
| 2022-10-11 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-05-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-04-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 재개 | Evercore ISI | In-line |
| 2021-02-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-02-02 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-01-06 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-01-06 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | 개시 | Mizuho | Neutral |
| 2020-08-06 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | 개시 | Barclays | Underweight |
| 2020-06-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | 재개 | Credit Suisse | Outperform |
| 2020-04-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-11 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | 개시 | Deutsche Bank | Hold |
| 2019-07-10 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | 개시 | Guggenheim | Buy |
| 2019-04-10 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-02-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-01-17 | 개시 | UBS | Buy |
| 2018-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-10-26 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | 개시 | Berenberg | Buy |
| 2018-07-17 | 재개 | Stifel | Hold |
| 2018-04-09 | 개시 | MoffettNathanson | Buy |
| 2018-03-12 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | 개시 | JP Morgan | Neutral |
| 2017-09-22 | 개시 | William Blair | Outperform |
모두보기
Cencora Inc 주식(COR)의 최신 뉴스
Securities Fraud Investigation Into Cencora, Inc. (COR) Announced - The National Law Review
TD Cowen reiterates Cencora stock Buy rating on generics thesis - Investing.com
TD Cowen reiterates Cencora stock Buy rating on generics thesis By Investing.com - Investing.com Australia
Cencora (NYSE:COR) Could Be A Buy For Its Upcoming Dividend - simplywall.st
Cencora, Inc. (COR) Stock Analysis: A 36.74% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Cencora Inc. stock (US15135B1017): Healthcare distribution leader posts solid Q2 results - AD HOC NEWS
Cencora Inc. stock underperforms Wednesday when compared to competitors - MSN
Cencora hits 52-week low after guidance cut - MSN
Cencora Q2 Earnings Call Highlights - Yahoo Finance
MSN Money - MSN
Can Cencora (COR) Sustain Its Margin Gains While Accepting Slower Revenue Growth? - simplywall.st
Cencora (COR) Q2 2026 EPS Surge Tests Bullish Earnings Growth Narratives - Sahm
Cencora Inc. stock (US15135B1017): Shares plunge after earnings and securities probe news - AD HOC NEWS
Securities Fraud Investigation Into Cencora, Inc. (COR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - ChartMill
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora Inc. Stock (US15135B1017): Q2 2026 Earnings Miss Weighs on Shares - AD HOC NEWS
McKesson's Fiscal 2027 Guidance 'Encouraging,' Cencora Selloff Overdone, Morgan Stanley Says - Moomoo
Cencora, Inc. Stock 12‑Month Price Target Cut to $365.17, Implies 43% Upside - TradingView
Cencora Earnings Review: The Selloff Was Overdone In My View (NYSE:COR) - Seeking Alpha
Why Is Cencora Stock Trading Lower On Wednesday? - Sahm
Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks? - Yahoo Finance
UBS Adjusts Price Target on Cencora to $412 From $410, Maintains Buy Rating - Moomoo
Cencora Q2 FY2026 slides: strategic moves amid revenue miss By Investing.com - Investing.com Australia
Cencora lifts 2026 outlook after OneOncology-fueled earnings jump - The Globe and Mail
Cencora Inc stock hits 52-week low at $265.50 By Investing.com - Investing.com Canada
Cencora: Fiscal Q2 Earnings Snapshot - theheraldreview.com
Cencora (COR) Valuation Check As Earnings Growth Follows Specialty Pharma And Acquisition Gains - simplywall.st
Cencora raises annual guidance despite quarterly miss - marketscreener.com
Cencora Plunges 17.7% Amid Sector-Wide Selling - AlphaStreet
Cencora, Inc. 2Q 2026: Revenue $78.36B, EPS $8.4— 10-Q Summary - TradingView
Oncology acquisitions lift Cencora (NYSE: COR) Q2 2026 profit and revenue - Stock Titan
Cencora, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
Cencora (COR) Raises 2026 EPS Outlook After Revenue Miss as International Growth Outpaces Domestic - AlphaStreet
Pricing Headwinds and Industry Trends Cut Into Cencora's 2026 Sales, but Fundamentals Remain Strong - Morningstar
Cencora, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Cencora Q2 FY2026 slides: strategic moves amid revenue miss - Investing.com
COR Stock Falls on Q2 Earnings & Revenue Miss, FY26 EPS View Raised - TradingView
Earnings call transcript: Cencora Inc. Q2 2026 misses estimates, stock drops - Investing.com
Cencora slides 17.6% after fiscal Q2 results miss revenue expectations and highlight near-term headwinds - Quiver Quantitative
Transcript : Cencora, Inc., Q2 2026 Earnings Call, May 06, 2026 - marketscreener.com
Cencora, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:COR) 2026-05-06 - Seeking Alpha
Cencora Inc stock hits 52-week low at $265.50 - Investing.com
Cencora raises annual profit forecast despite quarterly miss - marketscreener.com
Cencora (COR) Misses Q2 Earnings and Revenue Estimates - Yahoo Finance
Cencora (NYSE:COR) Falls on Earnings Miss Despite Revenue Beat as Guidance Update Fails to Impress - ChartMill
Cencora shares fall 2% on second quarter earnings miss By Investing.com - Investing.com Canada
Cencora shares fall 2% on second quarter earnings miss - Investing.com
Earnings Flash (COR) Cencora, Inc. Reports Q2 Revenue $78.36B, vs. FactSet Est of $81.09B - marketscreener.com
Earnings Flash (COR) Cencora, Inc. Posts Q2 Adjusted EPS $4.75 per Share, vs. FactSet Est of $4.82 - marketscreener.com
CENCORA ($COR) Releases Q2 2026 Earnings - Quiver Quantitative
Cencora Reports Fiscal 2026 Second Quarter Results - Quantisnow
Cencora Inc (COR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
6.57%
자본화:
|
볼륨(24시간):